UK based Theragnostics Ltd has obtained rights to an inhibitor of the poly ADP-ribose polymerase (PARP) enzyme in order to develop a new diagnostic for cancer. The licensing agreement is with AstraZeneca Plc and also includes an option to develop a radionuclide-labelled PARP inhibitor. AstraZeneca markets the PARP inhibitor Lynparza.
Financial terms of the agreement were not disclosed.